Visionhealth secures €1 million for its digital health app Kata. Investor Georg Matheis is leading the financing round. In addition to existing investors, several other entrepreneurs and investors are participating in the seed round.
Through digital monitoring of inhalation treatments, the Kata app aims to improve patient quality and reduce the costs of intensive care. The app is certified as a medical device. Visionhealth intends to use the funding to advance the approval process in Germany. The goal is for health insurance companies to reimburse the costs of the app. The company is also preparing Startup is planning to enter the German market and wants to expand the functionality of the app and validate it clinically.
Sabine Häußermann, CEO and founder of Visionhealth, says:
"We are very pleased that we have been able to generate such strong interest and support for our business model and are also proud to have successfully completed the financing round recently. We are confident that with Kata, we are bringing a medical device to market that will sustainably improve patients' daily lives and inhalation therapy. We now have the resources to integrate additional inhalers into our system and make the features of the Kata app accessible to an even broader patient group."
“Visionhealth has assembled an excellent team”
The seed investor Georg Matheis says:
"The therapeutic potential of Kata is very high for a wide range of patients with asthma or COPD. Kata's technology is based on many years of experience and in-depth knowledge of common patient errors. This is where the Kata app can offer real added value for patients, families, and treating physicians. Digital therapy support will gain importance in the healthcare sector in the future and will soon become part of everyday practice and clinical practice. Visionhealth has recognized this need and assembled an outstanding team that can contribute its extensive experience in respiratory diseases, existing therapeutic approaches, and the industry."
